PG Electroplast Limited Production Normalization Following LPG Supply Challenges

PG Electroplast Limited (PGEL) has informed stakeholders regarding its successful mitigation of production constraints related to LPG supply, which were caused by ongoing geopolitical tensions in the Middle East. The company swiftly identified and installed alternative energy solutions at its manufacturing facilities. As a result, production of Room AC units has nearly normalized, effectively addressing the recent challenges to a large extent for the immediate future.

Update on Production Constraints

PG Electroplast Limited (PGEL) has provided an important update concerning operational challenges previously communicated on March 09, 2025. The company was facing constraints related to the supply of LPG gas, as suppliers restricted shipments due to the ongoing conflict in the Middle East region. This restriction was specifically impacting the production of Room AC units across several of the company’s plants.

Proactive Energy Source Transition

In response to these evolving external factors, PGEL stated that it was continuously assessing the situation and actively exploring alternate energy sources for its operations. The company confirmed that it was successful in identifying and installing an alternative solution to LPG at its production facilities.

Normalization of Room AC Production

Following the successful installation and commissioning of the new energy infrastructure, PGEL confirms that the current Room AC production is almost normalized. The management believes that the implemented solution has successfully addressed the LPG-related challenges to a significant degree for the time being, ensuring continued supplies to customers.

This confirmation was officially issued on March 25, 2026, and is provided for the information and record of the exchanges.

Source: BSE

Previous Article

Kajaria Ceramics Completes 100% Acquisition of Kajaria Surfaces, Making It a Wholly-Owned Subsidiary

Next Article

Lupin Limited Receives Tentative FDA Approval for Pitolisant Tablets in the U.S.